Sorrento Therapeutics and researchers at Israel's Ben-Gurion University of the Negev are partnering to develop anti-hepatitis C antibodies. Under a collaborative agreement with the San Diego-based B.G. Negev Technologies and Applications, the university's technology company, Sorrento is licensing several fully human anti-HCV antibody clones from patients who have recovered from HCV infections. Sorrento says it plans to develop these antibody clones into a potential new therapeutic to treat the disease, which contributes to 15,000 deaths annually and is a leading cause of liver transplantations in the U.S. Release